• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, Sept. 25

Suven Life Sciences Ltd has received permission from the Drug Controller-General of India (DCGI) to conduct phase I clinical trials for its compound for the treatment of Alzheimer’s disease. The Hyderabad-based company is also in discussion with potential licensing partners for this compound (Suven 502). Timing of the licensing would depend on the deal terms and ability to get co-promotion rights in some of the regulated markets. The company is hoping to launch the c ompound in 2012. Other molecules in the same category currently under development include GSK’s molecule presently in Phase II, according to a release.

— Our Bureau

More Stories on : Research & Development | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line